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44Host CD251CD41Foxp31 Regulatory T Cells Primed
by anti-CD137 mAbs Inhibit Graft-versus-Host Disease
Juyang Kim,1 Wongyoung Kim,1 Hyun J. Kim,2 Sohye Park,2 Hyun-A. Kim,2 Daehee Jung,2
Hye-Jung Choi,3 Sang J. Park,4 Robert S. Mittler,4 Hong R. Cho,1,4 Byungsuk Kwon1,21 1 1CD25 CD4 Foxp3 regulatory T cells (Tregs) play a pivotal role in the maintenance of self-tolerance and
regulation of immune responses. Previous studies have demonstrated that CD137 signals can promote pro-
liferation and survival of Tregs in vitro. Here, we show that in vivo CD137-induced expansion of Tregs in naive
mice was dependent upon IL-2 secreted by memory T cells. Tregs primed by anti-CD137 mAbs had a higher
immunosuppressive capacity. Preconditioning with anti-CD137mAbs significantly inhibited graft-versus-host
disease (GVHD) in the C57BL/6/ (C57BL/6DBA/2) F1 acute GVHDmodel. In this disease model, a high
proportion of host Tregs remained long-term in the recipient spleen, whereas donor hematopoietic cells
replaced other host bone marrow-derived cells. Transient depletion of Tregs before transfer of donor cells
completely abrogated the inhibitory effect of anti-CD137 mAbs on GVHD. In addition, adoptive transfer of
anti-CD137-primed Tregs ameliorated GVHD. Our results demonstrate that it is possible to enhance the
survival and/or the immunosuppressive activity of host Tregs in nonmyeloablative GVHD, and that 1 way
of accomplishing this is through the prophylactic use of anti-CD137 mAbs in nonmyeloablative GVHD.
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A variety of model systems have been developed to
examine graft-versus-host disease (GVHD). In the
semiallogeneic (parent-into-F1) GVHDmodel, trans-
fer of parent lymphocytes into unconditioned F1
hybrid mice induces GVHD, because the host T cells
cannot actively suppress or kill donor alloreactive
T cells. This animal model may be appropriate for
human GVHD that develops after nonmyeloablative
conditioning of transplants to reduce toxicity [1].1Biomedical Research Center, Ulsan University Hospital,
l of Medicine, University of Ulsan, Ulsan, Korea; 2School
ological Sciences, University of Ulsan, Ulsan, Korea;
rtment of Pathology, Ulsan University Hospital, School
dicine, University of Ulsan, Ulsan, Korea; and 4Depart-
of Surgery, Ulsan University Hospital, School of
ine, University of Ulsan, Ulsan, Korea.
isclosure: See Acknowledgments on page 53.
dence and reprint requests: Byungsuk Kwon, PhD,
l of Biological Sciences, University of Ulsan, Ulsan,
(e-mail: bkwon@mail.ulsan.ac.kr) and Hong R. Cho,
PhD, Department of Surgery, Ulsan University Hospital,
rsity of Ulsan, Ulsan, Korea (e-mail: hrcho@uuh.ulsan.kr).
uly 29, 2011; accepted September 20, 2011
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2011.09.004This model is unique among GVHD models in
that the development of GVHD is initiated only by
alloreactivity without an inflammatory environment
induced by conditioning [2,3]. This property is useful
in dissecting various issues related to alloimmune
responses, including interactions between donor
T cells and host hematopoietic cells.
Host cells that survive irradiation have demonstra-
ble effects on GVHD [4-6]. For example, host
CD251CD41 regulatory T cells (Tregs) that persist
after lethal radiation can ameliorate GVHD [6].
Because of the advent of reduced intensity condition-
ing, host Tregs are likely to remain in recipients for
a prolonged time after hematopoietic stem cell trans-
plantation and control the incidence and severity of
GVHD. If this is true, modulation of host Tregs could
be employed as a prophylactic strategy for preventing
GVHD.One promising approach for suchmodulation
is to stimulate costimulatory pathways that are in-
volved in the expansion of Tregs.
CD137, the prototype costimulatory molecule for
CD81 T cells, is constitutively expressed on Tregs,
andCD137 signals are known topromote their prolifer-
ation and survival in vitro, especially in the presence of
IL-2 [7,8]. Based on this and the observation that
in vivo engagement of CD137 induces expansion of
memoryTcells in anAg-independentway,wepredicted
that agonistic anti-CD137 mAbs would increase Treg
cell numbers in the absence of Ag priming in
Biol Blood Marrow Transplant 18:44-54, 2012 45Role of Host Regulatory T Cells in GVHDnaivemice. In addition,wepostulated that in the parent-
into-F1 acute GVHD (aGVHD) model, host Tregs
might be relatively resistant to donor T cell attack,
because they have the ability to counterattack effector
T cells through production of immunosuppressive
mediators and cytotoxic molecules [9], and that residual
host Tregs could regulate GVHD mediated by donor
T cells in F1 recipients who receive nonmyeloablative
conditioning. Finally, to examine issues combining
these 2 hypotheses, we tested the feasibility of using
anti-CD137 mAbs as a GVHD prophylactic. In the
present study, we demonstrated that host Tregs primed
in the presence of anti-CD137 mAbs significantly
reduced GVHDmorbidity.MATERIALS AND METHODS
Mice
Female C57BL/6 (B6) (H-2b) and (B6  DBA/2)
F1 (BDF1) (H-2b/d) mice, 8 weeks of age, were pur-
chased from Orient (Seoul, Korea). All mice were
maintained in pathogen-free conditions. The Animal
Care Committee of University of Ulsan approved
these studies.
Abs
Anti-CD137 (3H3) and anti-CD25 (PC61.5)
mAbs were purified from ascites. Control rat IgG
was purchased from Sigma-Aldrich (St. Louis, MO).
The following FITC-, PE-, PerCP-, or biotin-
conjugated mAbs to mouse proteins were purchased
from BD Biosciences (San Diego, CA) or e-Bioscience
(San Diego, CA): CD4, CD8, CD25, CD39, CD44,
CD62L, CD127, H-2d, IL-2, and Foxp3.
Isolation of Splenocytes and Hepatic
Mononuclear Cells
The spleens and livers of BDF1 mice were har-
vested after antibody treatment and/or parental cell
transfer on the indicated days. Single-cell suspensions
in phosphate-buffered saline (PBS) were prepared
from the spleens, filtered through a sterile nylon
mesh (40.0 mm; BD Falcon, San Diego, CA), and
washed. After the erythrocytes were lysed in hemolysis
buffer (144.0 mMNH4Cl and 17.0 mMTris-HCl; pH
7.2), the remaining cells were resuspended in a staining
buffer (PBS containing 0.2% bovine serum albumin/
0.1% sodium azide). The livers were cut into small
pieces in PBS and incubated in the presence of
0.5 mg/mL type II collagenase (GIBCO Laboratories,
Grand Island, NY) at 4C for 2 h. The digested pieces
were minced and passed through a mesh. Hepatic cells
then were collected by centrifugation at 50  g for
10 minutes to remove tissue debris. After lysis of the
erythrocytes, the remaining cells were resuspended in
37% Percoll (GE Healthcare Biosciences, Uppsala,Sweden). The cell suspensions were gently overlayed
on 70% Percoll and centrifuged at 800 g for 25 min-
utes. Hepatic mononuclear cells were collected from
the interface, washed twice in PBS, and resuspended
in a staining buffer.
Flow Cytometry
Purified splenocytes and hepatic mononuclear
cells were preincubated in a blocking buffer (PBS con-
taining 2.4G2 mAbs/0.2% bovine serum albumin/
0.1% sodium azide), and then incubated with the rele-
vant mAbs at 4C for 30 minutes. Finally, the cells
were washed twice with a staining buffer and analyzed
by FACS Canto or FACS Calibur (BD Biosciences).
Intracellular Foxp3 staining was performed, according
to the manufacturer’s protocol (e-Bioscience).
Suppression Assay
Splenocytes were harvested from BDF1 mice
7 days after antibody treatment and from naive B6
mice. Collected splenocytes were suspended in
aMACS buffer (1 PBS containing 5.0 mM ethylene-
diaminetetraacetate and 3% calf serum) and incubated
with anti-CD4-conjugated microbeads (Miltenyi Bio-
tec, Auburn, CA) and anti-CD25 mAbs for 20 minutes
at 4C. CD41 T cells were enriched using MACS
(Miltenyi Biotec). FACS Aria (BD Biosciences) was
used to further purify CD41CD25hi T cells or
CD41CD252 T cells from MACS-isolated cells (the
purity routinely reached 98%-99%). CD41CD25hi
BDF1 T cells were cocultured with CD41CD252
B6 T cells (2  105) at various ratios in the presence
of 0.5 mg/mL anti-CD3 and anti-CD28 mAbs for
3 days. Proliferation on day 3 was assessed in triplicate
by pulsing with 1.0 mCi [3H]-thymidine added during
the final 12 hours. In some cases, culture medium was
harvested to measure cytokine levels after a 48-hour
culture. Cytokine concentrations were assessed using
the cytometric bead array (CBA) kit, according to the
manufacturer’s protocol (BD Biosciences).
In Vitro MLR Assay
Responder B6 CD41CD252 T cells were purified
as described above, labeled with 5.0 mM CFSE for
10minutes at 37C, and washed thoroughly before cul-
ture. Stimulator CD11c1 dendritic cells (DCs) were
enriched from BDF1 splenic cells using anti-CD11c
microbeads (Miltenyi Biotec). Anti-CD137-primed
BDF1 CD41CD25hi T cells were purified from BDF1
mice as described above. Responder B6 CD41CD252
Tcells (5 105 cells/well in a 24-well plate) were cocul-
tured with stimulator BDF1 CD11c1 DCs (2  106
cells/well) in the presence of various amounts of anti-
CD137- or control IgG-primed BDF1 CD41CD25hi
T cells. Three days later, cells were harvested and
stained with anti-CD4 mAbs and dilution of CFSE
46 Biol Blood Marrow Transplant 18:44-54, 2012J. Kim et al.was analyzed for responder B6CD41CD252Tcells by
flow cytometry. Culture medium was also harvested to
measure cytokine levels after 72-hour culture. Cytokine
concentrationswere assessedusing theCBAkit, accord-
ing to themanufacturer’s protocol (BDBiosciences). In
some experiments, splenocytes were isolated from
GVHD BDF1 mice and used as responder cells. Stim-
ulator CD11c1 DCs were enriched from normal
BDF1 mice as described above and irradiated with
g-rays (18 Gy) before coculture. The thymidine incor-
poration assay was performed as described in the
previous section.
Induction of GVHD
Single-cell suspensions from the spleens and
lymph nodes of normal B6 parental donors were pre-
pared in PBS at a concentration of 5  107 cells/
0.2 mL. Bone marrow (BM) cells were collected by
flushing the femurs and tibias from B6 donor mice
into MACS buffer. After erythrocyte lysis in hemolysis
buffer, the remaining cells were incubated with bioti-
nylated anti-CD3 mAbs for 20 minutes on ice, washed
once, then incubated with streptavidin-conjugated mi-
crobeads (Miltenyi Biotec) for 20minutes at 4C. Cells
were depleted of CD31 cells using MACS (Miltenyi
Biotec). The remaining CD31 cells were routinely
composed of\1% BM cells. Cells were resuspended
at 5  106 cells/0.2 mL in PBS before transplantation.
GVHD was induced by transfer of 5  106 BM cells
and 5  107 spleens/lymph node cells into the tail
vein of BDF1 mice that received 200 or 400 cGy
from a cesium irradiator. Antibodies were adminis-
tered i.p. on the indicated days. For some experiments,
CD41CD25hi T cells were purified from BDF1 mice
7 days after treatment with anti-CD137 mAbs or con-
trol IgG (200 mg/mouse) and adoptively transferred
into naive BDF1 mice (5  105 cells per mouse).
GVHD was induced as described above 7 days after
adoptive transfer.
Pathological Scoring of GVHD
Formalin-fixed livers and distal colonswere embed-
ded in paraffin, and 5-mm-thick sections were stained
with H&E for histologic examination. Slides were
coded and examined in a blinded fashion by 1 individual
(H.-J.C.), using a semiquantitative system for abnor-
malities known to be associated with GVHD [10,11].
Statistical Analysis
GraphPad Prism 4 (GraphPad Inc., La Jolla, CA)
was used to analyze and present the data. Differences
between 2 or .3 experimental groups were analyzed
by the Mann-Whitney or Kruskal-Wallis tests
followed by a post hoc Dunn’s test, respectively. The
log-rank test was used to compare survival between
experimental groups. Values are expressed as themean6 SEM. A P\ .05 value was considered statisti-
cally significant.RESULTS
Expansion of Tregs by anti-CD137 mAbs in
Naive Mice
To examine the effect of agonistic anti-CD137
mAbs on Tregs in naive mice, we administered anti-
CD137 mAbs in naive BDF1 mice, and the number
of CD41Foxp31 Tregs in the spleen and liver was
counted 7 days later. Treatment with anti-CD137
mAbs significantly increased Treg cell numbers in
both organs, but the extent was more drastic in the
liver (Figure 1A). There was no expansion of
Tregs in mice that received control rat IgG compared
with untreated na€ıve mice (data not shown). The ma-
jority of expanding Tregs expressed CD39
(Figure 1B) but not CD127 (data not shown). Re-
cently, this phenotype was shown to denote activated
memory Tregs in human peripheral blood that are
thought to have higher immunosuppressive function
[12]. Because IL-2 is required for the proliferation of
Tregs, we measured serum IL-2 and found that the
levels increased after anti-CD137 administration
(Figure 1C). The source of IL-2 might be from mem-
ory T cells, because they are the only type of T cells
known to respond to anti-CD137 mAbs in an Ag-
independent manner [13,14]. Indeed, treatment with
anti-CD137 mAbs significantly increased the number
of CD41 and CD81 T cells that express high levels
of CD44, a marker for memory T cells, in the spleen
(data not shown). More important, a greater propor-
tion of these T cells were positive for intracellular
IL-2 in anti-CD137-injected versus control IgG-
injected mice (Figure 1D). There was no measurable
IL-2 production in CD44low T cells of either group
of mice (data not shown). Neutralization of IL-2 abro-
gated the effect of anti-CD137 mAbs on the expansion
of Tregs partially in the spleen and completely in the
liver (Figure 1E), confirming that anti-CD137 mAbs
promote Ag-independent growth for memory T cells
and subsequently result in proliferation of Tregs
through IL-2.
Tregs Primed by anti-CD137 mAbs Have Higher
Immunosuppressive Activity
To determine whether priming of Tregs by anti-
CD137 mAbs had an effect on their immunosuppres-
sive activity, we cocultured CD252CD41 T cells
purified from B6 mice (a donor strain in our GVHD
setting), in the presence of anti-CD3 and anti-CD28
mAbs, with CD25hiCD41 Tregs of BDF1 mice that
were treated with control IgG or anti-CD137 mAbs.
As shown in Figure 2A, Tregs primed by anti-
CD137 mAbs were significantly more inhibitory than
Figure 1. Anti-CD137 mAbs induce the expansion of Tregs in an IL-2-dependent fashion. (A) Anti-CD137 mAbs or control IgG (200 mg per mouse)
were intraperitoneally administered into BDF1 mice. Splenocytes and liver mononuclear cells were harvested 7 days after antibody treatment, stained
with anti-CD4 and anti-Foxp3 mAbs, and analyzed by flow cytometry. Results are expressed as absolute cell numbers of splenic and hepatic
CD41Foxp31 T cells. *P\.05 between the 2 groups (n 5 5 per group). Results are representative of 3 independent experiments. (B) Experiments
were conducted as described above. Splenocytes were triple stained with anti-CD4, anti-Foxp3, and anti-CD39 or anti-CD127 mAbs, and analyzed
by flow cytometry. Data are shown as percentages of CD391 cells of CD41Foxp31 T cells. CD127 was not expressed on CD41Foxp31 T cells.
***P\ .01 between the 2 groups (n 5 5 mice per group). (B) Serum was harvested 3 days after antibody treatment. Levels of IL-2 were measured
using the CBA assay. *P\ .05 between the 2 groups (n 5 5 per group). (C) Splenocytes harvested 3 days after antibody treatment were triple
stained with anti-CD44, anti-IL-2, and anti-CD4 or anti-CD8 mAbs, and analyzed by flow cytometry. Data are shown as percentages of IL-21 cells
of CD44hiCD41 or CD44hiCD81 T cells. *P\ .05 and **P\ .01 between the 2 groups (n 5 5 mice per group). Results are representative of 3
independent experiments. (D) BDF1 mice were administered with anti-IL-2 mAbs (1.0 mg/mouse) and anti-CD137 mAbs (200 mg/mouse) at a day
interval. Seven days later, splenocytes and hepatic mononuclear cells were analyzed as described in (A). Data are shown as percentages of Foxp31 cells
of CD41 T cells. *P\.05 and **P\.01 between the 2 groups (n 5 5 per group). Results are representative of 3 independent experiments.
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using one-fourth of responding T cells, compared with
those primed by control IgG. In this culture condition,
significantly lower levels of cytokines were detected in
culture media containing anti-CD137-primed Tregs
versus control IgG (Figure 2B). Because the extent of
cytokine down-regulation (except for interferon
[IFN]-g) by Tregs primed by control IgG was remark-
able in activating CD41 T cells, we concluded that
anti-CD137 mAbs had a distinguishable effect on theimmunosuppressive activity of Tregs. As of yet, it is
unclear why Tregs do not inhibit IFN-g production
by activated CD41 T cells. One explanation for this
observation might be that IFN-g production by Tregs
offsets their inhibition of IFN-g production by acti-
vated CD41 T cells [15].
We next examined the activity of BDF1 Tregs
primedby anti-CD137mAbsor control IgG to suppress
the responsiveness of B6 CD252CD41T cells to allos-
timulation with enriched BDF1 splenic CD11c1 DCs.
Figure 2. Tregs primed by anti-CD137 mAbs have a higher immunosuppressive capacity. (A, B) Splenocytes were harvested from BDF1 mice 7 days
after treatment with anti-CD137mAbs or control IgG and from naive mice. BDF1 CD41CD25hi T cells and B6 CD41CD252 T cells were purified using
FACS Aria after enrichment with MACS. (A) Responding B6 CD41CD252 T cells (2  105 cells/well) were cocultured in triplicate with BDF1
CD41CD25hi T cells at the indicated ratio in the presence of anti-CD3/CD28 mAbs (0.5 mg/mL each) for 3 days. Proliferative activity was determined
by a conventional [3H]thymidine incorporation assay. Data are shown as the mean6 SEM. *P\.05, **P\.01, and ***P\.001 between the 2 groups at
the indicated ratios (n 5 5 per group). Results are representative of 3 independent experiments. (B) Levels of IL-2, IL-4, IL-5, and IFN-g contained
in 3-day culture supernatants of Treg:Tresp (responder T cells) 5 0.25:1 or Tresp only were measured using the CBA assay. Data are shown as the
mean 6 SEM (n 5 5 per group). ***P\ .001, **P\ .01, and *P\ .05 between the 2 groups. (C, D) Experiments were set as described in A. (C)
BDF1 CD41CD25hi T cells and B6 CD41CD252 T cells were purified as described above. CD11c1 DCs were enriched using MACS. CFSE-labeled
responder B6 CD41CD252 T cells (5  105 cells/well) were cocultured with BDF1 CD41CD25hi T cells at the indicated ratios in the presence
of enriched BDF1 CD11c1 DCs (1  106 cells/well) for 3 days. Percentages of dividing B6 CD41CD252 T cells are shown. (D) Levels of cytokines
contained in 3-day culture supernatant were measured using the CBA assay. Results are representative of 2 independent experiments.
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Figure 3. A large number of residual host Tregs exist in the spleen of GVHD mice. GVHD was induced by transferring 5  107 B6 spleen/lymph node
and 5 106 T cell–depleted BM cells into BDF1mice that were conditioned with 2 Gy (A, B) or 4 Gy (C, D). The recipient BDF1mice received 200 mg of
anti-CD137 mAbs or control IgG 1 week before GVHD induction. Splenocytes were harvested 130 days after GVHD induction and were triple stained
with anti-H-2d, anti-CD4, and anti-Foxp3 mAbs, and H-2d-negative and positive CD41 T cells were gated and analyzed for Foxp3 expression. (A, C) The
MFI (mean fluorescent intensity) against Foxp3 in host and donorCD41 T cells was analyzed by flow cytometry. (B, D) Shown are percentages of Foxp3hi
cells of CD41 T cells. Data shown are presented as the mean 6 SEM (n 5 9-12 per group). ***P\.001 between the 2 groups.
Biol Blood Marrow Transplant 18:44-54, 2012 49Role of Host Regulatory T Cells in GVHDIn this MLR assay, anti-CD137-primed Tregs were far
more potent in inhibiting proliferation of alloreactive
CD41 T cells and their production of cytokines than
control IgG-primed Tregs (Figure 2C and D). The
in vitro results suggest the possibility that host Tregs
primed by anti-CD137mAbs could have a beneficial ef-
fect onGVHDbysuppressing the activityof alloreactive
donor T cells in vivo.
Persistence of Host Tregs in the B6/ BDF1
GVHD Model
Host Tregs are more resistant to radiation relative
to other hematopoietic cells [16] andmaintain the abil-
ity to inhibit GVHD even after lethal irradiation [6].
This suggests that rescue of host Tregs might amelio-
rate GVHD. The B6/ BDF1 GVHDmodel appears
to be a good experimental system for addressing this
issue, because GVHD can be induced with mild or
no conditioning. We induced GVHD by transferring
B6 spleen/lymph node and BM cells into BDF1 mice
that received 200 or 400 cGy total body irradiation
(TBI). A large number of host CD41 T cells were
evident in the spleen 3 months after GVHD induction
and a majority of them expressed higher levels of
Foxp3, compared with CD41 T cells derived from
the donor (Figure 3A and C). The portion of Foxp3hi
cells in the host CD41 T cell fraction was greater in
BDF1 mice conditioned with 200 cGy versus 400
cGy (Figure 3B andD). In the same set of experiments,
we wanted to examine the effect of anti-CD137 mAbson the survival of host Tregs in GVHDmice. A signif-
icant number of Foxp3hi host Tregs were present in the
spleen of mice preconditioned with anti-CD137 mAbs
3 months after GVHD induction, and the number of
Foxp3hi host Tregs in the host CD41 T cell fraction
was comparable to that of GVHD mice that were
not preconditioned with anti-CD137 mAbs
(Figure 3B and D). It should be noted that GVHD
mortality and morbidity correlated with the intensity
of TBI (data not shown).
Preconditioning with anti-CD137 mAbs
Decreases the Severity of GVHD through
Host Tregs
Because anti-CD137mAbs were shown to increase
the immunosuppressive activity of Tregs, we predicted
that preconditioning with anti-CD137 mAbs would
ameliorate GVHD. BDF1 mice preconditioned with
anti-CD137 mAbs maintained higher body weight ex-
cept for several time points throughout GVHD pro-
gression than control BDF1 mice (Figure 4A). Even
though there was no difference in survival rate in this
mild GVHD model, FACS analysis for splenocytes
showed that preconditioning with anti-CD137 mAbs
prevented severe lymphodepletion, a parameter for
aGVHD (Figure 4C). Consistent with this, a lower
proportion of activated (CD62Llow) donor T cells
were present in the spleen of BDF1 recipients precon-
ditioned with anti-CD137 mAbs versus control IgG
(Figure 4D). In addition, their splenocytes had a lower
Figure 4. Preconditioning with anti-CD137 mAbs inhibits GVHD. BDF1 mice received 200 mg of anti-CD137 mAbs or control IgG and were recon-
stituted with 5 106 T cell–depleted BM cells plus 5 107 spleen/lymph node cells of B6 mice on day 21 after antibody treatment. (A) Change in body
weight (n5 23 per group). (B) Percentage of survival (n5 23 per group). (C-F) Splenocytes were harvested 70 days after GVHD induction. After count-
ing the number of total splenocytes, they were stained with anti-H-2d, CD62L, and anti-CD4 or anti-CD8 mAbs, and analyzed by flow cytometry. (C)
Numbers of total splenocytes. (D) Percentage of CD62Llow of donor CD41 or CD81 T cells. (E) MLR assay. Splenocytes (2  105 cells/well) were co-
cultured in triplicate with BDF1 CD11c1 dendritic cells (2  106 cells/well) or alone for 3 days. Proliferative activity was determined by a conventional
[3H]thymidine incorporation assay. (F) Percentage of donor cells in the spleen. Data shown in (C-F) are presented as themean6 SEM (n5 10 per group).
*P\.05 and **P\.01 between the 2 groups.
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DCs (Figure 1E). Nonetheless, preconditioning with
anti-CD137 mAbs had no influence on donor cell en-
graftment (Figure 3F). Our result suggests that pre-
conditioning with anti-CD137 mAbs can inhibit
GVHD by preventing donor T cell action (also see
Figure 5D for histopathologic scores).
To examine whether host Tregs were responsible
for the effect of anti-CD137 preconditioning on
GVHD, we transiently depleted host Tregs before
GVHD induction, using anti-CD25 mAbs [17].
Regardless of whether recipients were preconditioned,
the average body weight of recipients that were de-
pleted of host Tregs was lower at a majority of time
points during the development of GVHD than that
of nondepleted recipients (Figure 5A). A more severe
pattern of GVHD in mice that were depleted of host
Tregs was reflected in survival rate, lymphodepletion,and histopathology in GVHD target organs
(Figure 5B-D). These results indicate that the inhibi-
tory effects of anti-CD137 preconditioning on
GVHD did not occur in the absence of Tregs.
We further examined the immunosuppressive
activity of Tregs primed by anti-CD137 mAbs to con-
tribute to GVHD inhibition in vivo. We adoptively
transferred high purity Tregs primed by either anti-
CD137 mAbs or control IgG into BDF1 mice and
induced GVHD 7 days after adoptive transfer. Two-
month observations showed less severe GVHD in
3 parameters used to assess aGVHD, body weight,
lymphodepletion, and histopathology in mice that
received anti-CD137-primed Tregs versus control
IgG-primed Tregs (Figure 6A, C, andD), even though
statistically significant differences in survival rate and
liver histopathology were not found between the
2 groups (Figure 6B and D). Overall, our results
Figure 5. Anti-CD137-mediated inhibition of GVHD is dependent upon Tregs. BDF1 mice were administered with anti-CD137 mAbs or control IgG
(200 mg/mouse). Each group of mice was divided into 2 groups: 1 group of mice was injected with anti-CD25 (200 mg /mouse) and the other group with
control IgG on days 0, 14, and 21 (the day of anti-CD137 treatment is referred to as day 0). Twenty-one days later, mice were reconstituted with 5 106
T cell–depleted BM and 5 107 spleen/lymph node cells of B6 mice (n5 15-16 per group). Organs were harvested on day 91 after disease induction. (A)
Change in body weight (n5 15-16 per group). (B) Percentage of survival (n5 15-16 per group). *P\.001 between the indicated 2 groups. (C) Numbers
of total splenocytes. (D) Pathologic scores of colons and livers. Data shown in (C-D) are presented as the mean6 SEM (n5 5 per group). **P\.01 and
***P\.001 between the 2 groups.
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are able to ameliorate GVHD in the parent-into-F1
aGVHD model.DISCUSSION
Agonistic CD137-specific mAbs suppress disease
in mouse models of autoimmune encephalomyelitis
[18], asthma [19], arthritis [20], systemic lupus erythe-
matosus [21,22], and chronic GVHD [17,23]. A
consensus on how CD137 stimulation prevents
disease has yet to emerge, but it appears to be
involved in the hyperactivation of T cells, causing
them to acquire regulatory capacity or induce cell
death. In 2 preclinical models of chronic GVHD
featuring a systemic lupus erythematosus-like pheno-
type or scleroderma, agonistic anti-CD137 treatment
leads to the deletion of pathogenic CD41 T cells
[17,23]. Agonistic anti-CD137-mediated deletion of
CD41T cells occurred through Fas-dependent activa-
tion-induced cell death [22]. In this study, we showed
another characteristic property of agonistic anti-
CD137 mAbs to promote the proliferative and immu-
nosuppressive activity of Tregs in naive mice and
provided a potential way to use anti-CD137 mAbs asa prophylatic GVHD treatment for a nonmyeloabla-
tive GVHD and donor lymphocyte infusion GVHD.
Repeated treatment with agonistic anti-CD137
mAbs has a broad range of influences on peripheral
hematopoietic cells and hematopoiesis in the BM of
normal mice and in irradiated mice engrafted with
BM [24,25]. It appears that events mediated by anti-
CD137 mAbs result from their direct targeting of
CD137-expressing cells (CD81 T cells in particular)
and are indirectly affected by cytokines produced after
anti-CD137 treatment. For example, CD137 trigger-
ing induces massive apoptosis of B cells through
IFN-g produced by expanding CD81 T cells [24,25],
while directly resulting in activation-induced natural
killer and natural killer T cell death [25] and expansion
of memory T cells [12]. The current study demon-
strated that a single injection of anti-CD137 mAbs
increased CD44hi T cells producing IL-2 in normal
mice (Figure 1D).We believe that these cells are mem-
ory T cells, because they are the only known type of
T cells that can proliferate in response to anti-
CD137 mAbs in an Ag-independent way [13,14].
However, we cannot exclude the possibility that
there are other sources of IL-2 such as activated T cells
and DCs [26]. Tregs expanded by anti-CD137 mAbs
have the same phenotype of recently identified human
Figure 6. Tregs primed by anti-CD137 mAbs inhibit GVHD. CD41CD25hi T cells were purified from BDF1 mice 7 days after treatment with anti-
CD137 mAbs or control IgG (200 mg/mouse) and adoptively transferred into naive BDF1 mice (5  105 cells per mouse). Seven days later, they
were reconstituted with 5  106 T cell–depleted BM cells and 5  107 B6 spleen/lymph node cells after 4 Gy TBI. Organs were harvested on day
68 after disease induction. (A) Change in body weight (n 5 10 per group). (B) Percentage of survival (n 5 10 per group). (C) Numbers of total sple-
nocytes. **P\.01 between the 2 groups. (D) Pathologic scores of livers and colons. Data shown in (C-D) are presented as the mean 6 SEM (n 5
6-8 per group). **P\.01 between the 2 groups.
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are thought to have superior immunosuppressive ac-
tivities [12]. This observation raises the outstanding
question of whether it is a common feature of normal
memory T cells and memory Tregs to have a higher
capacity to proliferate in response to anti-CD137
mAbs. Because IL-2 seems to be essential for anti-
CD137-mediated expansion of Tregs (Figure 1E),
crosslinking the CD137 receptor on Tregs might
have a synergistic effect on their proliferation with
IL-2 produced by memory T cells. This hypothesis
is supported by 1 in vitro study showing that
strepavidin-CD137L fusion protein augments IL-2-
mediated proliferation of Tregs [8] and our
observation that neutralization of IL-2 could not com-
pletely abrogate anti-CD137-mediated proliferation
of Tregs (Figure 1E). Because applying a low dose of
IL-2 induces immune tolerance through the preferen-
tial expansion of Tregs [27-32], a combination of anti-
CD137 and IL-2may be considered to be a prophylaxic
use for nonmyeloablative GVHD.
Anti-CD137mAbs increase not only the expansion
of Tregs but also their immunosuppressive activity
(Figure 2). We found higher expression levels of
Foxp3 in CD41CD251 T cells of mice that received
anti-CD137 mAbs (our unpublished data). This result
suggests that 1 mechanism underlying the heightened
immunosuppressive activity of Tregs following anti-
CD137 treatment should occur through up-regulationof Foxp3, a master transcription factor, that controls
the expression of genes involving immunosuppression.
Another possibility is that their suppressive activity
increases in an anti-inflammatory cytokine (ie,
interleukin-10, transforming growth factor-b, and
IFN-g)-enriched milieu that follows anti-CD137
treatment. CD137 signals, in the presence of IL-2,
may directly induce the production of IL-10 and trans-
forming growth factor-b in Tregs and/or indirectly
through their production of IFN-g [15,33]. In
addition, a massive production of IFN-g in CD81
T cells may be associated with anti-CD137-mediated
immunosuppression of Tregs, as previously shown in
suppressor CD81 T cells generated following anti-
CD137 treatment [34]. Currently, we cannot exclude
the possibility that immunosuppressive cytokines pro-
duced by a variety of myeloid cells, natural killer cells,
natural killer T cells, and nonhematopoietic cells such
as endothelial cells [35] can contribute to the increased
immunosuppressive activity of Tregs that results from
anti-CD137 treatment.
It is surprising that anti-CD137-primed host
Tregs have the ability to suppress GVHD, considering
that host Tregs have been shown to be unable to pro-
tect recipient mice from lethal GVHD [36]. The ob-
servation that stimulator-type normal Tregs had
little effect on proliferation of responding CD41
T cells in an in vitro MLR assay [36], together with
the notion that activated Tregs can function in an Ag
Biol Blood Marrow Transplant 18:44-54, 2012 53Role of Host Regulatory T Cells in GVHDnonspecific way [37-39], strongly suggests that host
Tregs can be polyclonally activated by anti-CD137
mAbs to suppress activation of donor T cells via
allorecognition of stimulator. In addition, a large
number of host Tregs long-term survive conditioning
of a low dose of TBI and attack by donor T cells in our
GVHD model, while they may be rapidly eliminated
after GVHD induction in the more stringent GVHD
model that Strober and colleagues used [36].
A single 200-mg injection of anti-CD137 mAbs
after conditioning with TBI results in acute lethal
cytotoxicity [40]. It is thought that agonistic anti-
CD137 mAbs have adverse effects on acute inflamma-
tion [41]. In this study, we induced GVHD 3 weeks
after preconditioning with anti-CD137 mAbs to mini-
mize the potential toxicity of residual anti-CD137
mAbs in irradiated mice. Considering that this precon-
ditioning had beneficiary effects onGVHD,we believe
that the preserved immunosuppressive activity of host
Tregs primed by anti-CD137 mAbs might offset their
residual toxicity on GVHD. However, it should be
noted that preconditioning with anti-CD137 mAbs
marginally prolonged haplo-major hiscompatibility
complex-mismatched skin allograft survival (data not
shown). This result indicates that our approaches
have limitations for use in preventing allogeneic allo-
graft rejection. Another potential limitation for pre-
conditioning with anti-CD137 mAbs in clinical
situations is that graft rejection may occur if anti-
CD137 mAbs induce expansion and activation of host
memory T cells that have alloreactivity to donor cells.
Our results shown in Figure 6 indicate that transfer
of anti-CD137-primed Tregs may be a highly effective
way to inhibit GVHD. It may be possible to obtain
a large quantity of Tregs with a higher immunosup-
pressive activity in vitro using anti-CD137 mAbs (pre-
sumably in combination with other reagents such as
IL-2 and/or anti-CD3 mAbs). Those Tregs have clin-
ical merits, because anti-CD137 mAbs have limita-
tions for in vivo use because of their toxicity and
broad targets in the body. This issue is currently under
investigation in our laboratory.
In summary, host Tregs had long-term survival in
the host following BM transplantation and inhibit
GVHD in the B6/ BDF1 aGVHD model. Precon-
ditioning with anti-CD137 mAbs effectively prevents
GVHD in this setting by enhancing the immunosup-
pressive activity of host Tregs against alloreactive
donor T cells. Therefore, preserving host Tregs and
increasing their suppressive activity could be a valuable
approach for preventing GVHD, especially in a non-
myeloablative condition.ACKNOWLEDGMENTS
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